J3 Bioscience, Inc. Announces Appointment of Three New Directors to Board; Retirement of One
Salt Lake City, UT – May 23, 2024.
J3 Bioscience, Inc., a commercialization stage women’s health medical device company, today announced the appointment of three new members to its Board of Directors: John Fair, Dr. Keith Marmer, and Dr. Stephanie Singer.
John brings 20 years of experience in women’s health commercial strategy, fundraising and business development and currently serves as Global Head of Partnering & Corporate Development at Heranova Lifesciences. His insights and leadership will be invaluable as J3 Bioscience continues to commercialize its lead product, LivRing®.
Keith has 33 years’ experience in company formation, corporate strategy, leadership, business development, licensing, investment, technology development, patent strategy and clinical practice as an entrepreneur, executive and practitioner. He currently serves as Managing Partner of UVB Capital, a venture fund focused on partnering with early-stage life science companies. Prior to co-founding UVB Capital, Keith was Chief Innovation & Economic Engagement Officer at the University of Utah. His experience will be instrumental in guiding J3 Bioscience's strategic direction and growth.
Stephanie is a Board-certified OB/GYN since 1999, specializing since 2019 solely in gynecology, minimally invasive gynecologic surgery and women’s health, with great emphasis on hormone balance, sexual health and healthy aging. Her expertise will be essential as J3 Bioscience commercializes its lead product and develops its follow-on products with its patented ring platform.
Dr. Jayne Carney has advised the Company that she will retire from the Board later this month concurrent with her 80th birthday. The Company extends its deepest gratitude to Jayne for her eight years of service on the Company’s Board of Directors.
"We are very excited to enhance our Board with these high caliber professionals at this pivotal time for the Company," said R. Tyler McCabe, President and CEO of the Company. "Their contributions will help the Company achieve its strategic goals in many important ways."
With the addition of these three new directors and the retirement of Dr. Carney, J3 Bioscience's Board now consists of nine members with diverse backgrounds and expertise, further strengthening the company's governance and strategic oversight.
About J3 Bioscience
J3 Bio is a commercialization stage women’s health medical device company. The Company’s lead product, known as the LivRing® (formerly termed VR101), is an FDA cleared (K203377), patented and unique lubricating intravaginal ring (IVR). It is designed to moisturize and lubricate the vagina, enhance the ease and comfort of intimate sexual activity, and supplement the body's natural lubrication. It contains no hormones/drugs, is long-lasting (7 days each), and self-inserted weekly. It is the only IVR that provides long-lasting controlled-release of a moisturizing lubricant.
CONTACT:
R. Tyler McCabe, PhD
Chief Executive Officer, J3 Bioscience, Inc.
[email protected]
J3 Bioscience Receives FDA Clearance on Lead Product for Unmet Women’s Vaginal Health and Wellness Needs
PRESS RELEASE - October 27, 2021 – Salt Lake City, UT.
Patented LivRing® is an intravaginal ring that provides long-lasting, controlled release of moisture to supplement the body’s natural lubrication and enhance the ease and comfort of sexual activity.
J3 Bioscience, Inc. today announced that its first vaginal health product, known as the “LivRing®” (aka VR101 Lubricating Intravaginal Ring), recently received 510(k) Premarket Notification clearance from the U.S. Food and Drug Administration (FDA). The LivRing is a patented, intravaginal ring (IVR) that functions as a long-term (up to 7 days) lubricating vaginal moisturizer to supplement the body’s natural lubrication and enhance the ease and comfort of intimate sexual activity. The LivRing is the longest-lasting vaginal lubricating product that will be available over-the-counter (OTC).
The LivRing®
“LivRing will solve the substantial unmet vaginal discomfort need,” said R. Tyler McCabe, PhD, President/CEO of J3 Bioscience. “The Company is thrilled to receive FDA clearance on its first and lead product as this definitely will provide a benefit to certain women and women’s health.” In addition, Dr. McCabe noted, “The LivRing is an innovative product. It contains no drugs or hormones and releases a lubricating moisturizer. Each ring is long-lasting and effective for up to 7 days. In addition, it is safe, simple, and easy to self-insert. LivRing does not interrupt intimacy or spontaneity, and is intended for continuous, repeat use when each ring is replaced weekly. Clinical study participants reported very high satisfaction and confidence levels.”
While ideal for post-menopausal women, the LivRing was clinically tested in women 21 years and older who qualified for the study. Women who will benefit include those experiencing discomfort from vaginal dryness, including potential dryness from medications and certain medical conditions. The LivRing is the only OTC product that is intended to provide long-lasting (seven days each ring) controlled-release of a natural lubricating moisturizer. The Indications for Use are: LivRing (VR101 Lubricating Intravaginal Ring) is a personal lubricant for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity, and supplement the body’s natural lubrication. This product is compatible with natural rubber latex and synthetic (polyurethane and polyisoprene) male condoms and FC2 female condoms.
The LivRing is expected to be commercially available in the U.S. in the first half of 2022. Commercialization in Europe is expected later in 2022 after the product receives its CE mark.
About J3 Bioscience
J3 Bioscience, Inc., based in Salt Lake City, UT, is a commercialization-stage women’s health company focused on using its patented, proprietary technologies to create unique products addressing unmet needs for women’s vaginal health and wellness. The Company’s lead product, known as the LivRing, is a unique, clinically proven, and FDA-cleared intravaginal ring (IVR) that provides natural lubrication and moisture to women experiencing vaginal dryness. Using the same patent protected intellectual property platform, J3 Bioscience has programs in various stages of development for additional IVR products, including “light” LivRing, a pH balancing ring, and a probiotic ring.
CONTACT:
R. Tyler McCabe, PhD
Chief Executive Officer, J3 Bioscience, Inc.
[email protected]